Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas

Mantle cell lymphoma (MCL) comprises 3–10% of NHL, with survival times ranging from 3 and 5 years. Indolent lymphomas represent approximately 30% of all NHLs with patient survival largely dependent on validated prognostic scores. High response rates are typically achieved in these patients with curr...

Full description

Saved in:
Bibliographic Details
Main Authors: Marco Gunnellini, Lorenzo Falchi
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Advances in Hematology
Online Access:http://dx.doi.org/10.1155/2012/523842
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832554981665800192
author Marco Gunnellini
Lorenzo Falchi
author_facet Marco Gunnellini
Lorenzo Falchi
author_sort Marco Gunnellini
collection DOAJ
description Mantle cell lymphoma (MCL) comprises 3–10% of NHL, with survival times ranging from 3 and 5 years. Indolent lymphomas represent approximately 30% of all NHLs with patient survival largely dependent on validated prognostic scores. High response rates are typically achieved in these patients with current first-line chemoimmunotherapy. However, most patients will eventually relapse and become chemorefractory with poor outcome. Alternative chemoimmunotherapy regimens are often used as salvage strategy and stem cell transplant remains an option for selected patients. However, novel approaches are urgently needed for patients no longer responding to conventional chemotherapy. Lenalidomide is an immunomodulatory drug with activity in multiple myeloma, myelodisplastic syndrome and chronic lymphoproliferative disorders. In phase II studies of indolent NHL and MCL lenalidomide has shown activity with encouraging response rates, both as a single agent and in combination with other drugs. Some of these responses may be durable. Optimal dose of lenalidomide has not been defined yet. The role of lenalidomide in the therapeutic armamentarium of patients with indolent NHL or MCL will be discussed in the present paper.
format Article
id doaj-art-fafc90600f954ddd9c4b32e06dbe7b6a
institution Kabale University
issn 1687-9104
1687-9112
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Advances in Hematology
spelling doaj-art-fafc90600f954ddd9c4b32e06dbe7b6a2025-02-03T05:49:55ZengWileyAdvances in Hematology1687-91041687-91122012-01-01201210.1155/2012/523842523842Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s LymphomasMarco Gunnellini0Lorenzo Falchi1S. C. Oncohematology, Perugia University, S. Maria, 05100 Terni, ItalyS. C. Oncohematology, Perugia University, S. Maria, 05100 Terni, ItalyMantle cell lymphoma (MCL) comprises 3–10% of NHL, with survival times ranging from 3 and 5 years. Indolent lymphomas represent approximately 30% of all NHLs with patient survival largely dependent on validated prognostic scores. High response rates are typically achieved in these patients with current first-line chemoimmunotherapy. However, most patients will eventually relapse and become chemorefractory with poor outcome. Alternative chemoimmunotherapy regimens are often used as salvage strategy and stem cell transplant remains an option for selected patients. However, novel approaches are urgently needed for patients no longer responding to conventional chemotherapy. Lenalidomide is an immunomodulatory drug with activity in multiple myeloma, myelodisplastic syndrome and chronic lymphoproliferative disorders. In phase II studies of indolent NHL and MCL lenalidomide has shown activity with encouraging response rates, both as a single agent and in combination with other drugs. Some of these responses may be durable. Optimal dose of lenalidomide has not been defined yet. The role of lenalidomide in the therapeutic armamentarium of patients with indolent NHL or MCL will be discussed in the present paper.http://dx.doi.org/10.1155/2012/523842
spellingShingle Marco Gunnellini
Lorenzo Falchi
Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas
Advances in Hematology
title Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas
title_full Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas
title_fullStr Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas
title_full_unstemmed Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas
title_short Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin’s Lymphomas
title_sort therapeutic activity of lenalidomide in mantle cell lymphoma and indolent non hodgkin s lymphomas
url http://dx.doi.org/10.1155/2012/523842
work_keys_str_mv AT marcogunnellini therapeuticactivityoflenalidomideinmantlecelllymphomaandindolentnonhodgkinslymphomas
AT lorenzofalchi therapeuticactivityoflenalidomideinmantlecelllymphomaandindolentnonhodgkinslymphomas